(NASDAQ: OCUL) Ocular Therapeutix's forecast annual revenue growth rate of 23.34% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.71%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Ocular Therapeutix's revenue in 2025 is $56,664,000.On average, 5 Wall Street analysts forecast OCUL's revenue for 2025 to be $9,655,690,794, with the lowest OCUL revenue forecast at $8,990,333,069, and the highest OCUL revenue forecast at $11,796,875,984. On average, 5 Wall Street analysts forecast OCUL's revenue for 2026 to be $11,480,900,662, with the lowest OCUL revenue forecast at $9,684,574,001, and the highest OCUL revenue forecast at $14,424,203,821.
In 2027, OCUL is forecast to generate $20,227,988,413 in revenue, with the lowest revenue forecast at $11,013,897,489 and the highest revenue forecast at $27,642,620,760.